Advertisement

Topics

Caris Diagnostics Company Profile

07:15 EDT 23rd September 2017 | BioPortfolio

Caris Diagnostics (Caris Dx) is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. Caris Diagnostics provides world-class pathology services to physicians who treat patients in the community setting. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowship and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Diagnostics provides the highest levels of service to its customers and their patients through its state-of- the-art laboratories; proprietary, advanced clinical and technology solutions; and rigorous quality assurance programs. Through the molecular testing expertise of the Caris Molecular Profiling Institute (Caris MPI) at Caris Dx, the company also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to provide critical information to physicians treating cancer and other complex diseases. In addition, Caris MPI supports pharmaceutical companies and other researchers in their clinical trials for targeted therapeutics with custom genomic and proteomic analyses, analyte preservation, tissue procurement and comprehensive reporting services. The company has strategic relationships with the International Genomics Consortium, US Oncology, the Translational Genomics Research Institute, and the Biodesign Institute of Arizona State University. More than 2,000 physicians nationally use Caris Diagnostics. Formed in 1996, the company is headquartered in Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites); Newton, Massachusetts. Additional information is available at http://www.carisdx.com.


News Articles [1162 Associated News Articles listed on BioPortfolio]

Caris’ studies show use of molecular profiling to develop oncology therapies

US-based Caris Life Sciences has reported positive data from two studies conducted for the validation of its tumour molecular profiling approach to guide the development of therapeutic strategies.

Caris Life Sciences expands global reach of its tumour profiling service to Middle East and Africa

IRVING, Texas, Aug. 22, 2013 /PRNewswire/ -- Caris Life Sciences™, a leading biosciences company focused on fulfilling the promise of personalized medicine in oncology, has signed a distrib...

Caris Life Sciences Appoints John Marshall, M.D., as Chief Medical Officer

IRVING, Texas, May 17, 2017 /PRNewswire/ -- Caris Life Sciences, a leading innovator in molecular science, today announced the appointment of John Marshall, M.D., as its Chief Medical Officer. Dr. Mar...

System identifies patients with solid tumors more likely to respond to immunotherapy

Caris Life Sciences today highlighted an article published in Science containing data on microsatellite instability (MSI) status and mismatch repair (MMR)-deficient tumors on a wide range of tumor typ...

Co-Diagnostics, Synbiotics launch joint venture CoSara Diagnostics in India

Co-Diagnostics, a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, officially announced the recent incorporation of CoSara Diagnostics, a ...

IPO nets $6.4mm for Co-Diagnostics

Molecular diagnostics start-up Co-Diagnostics Inc. netted $6.4mm through its initial public offering of 1.18mm common shares at $6 each on the Nasdaq.

Tumor profiling technology highlights potential of precision oncology

The privately-held Texan biotech firm Caris Life Sciences presented data at the annual meeting of the…

Caris Life Sciences Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 26072017] Prices from USD $250

SummaryCaris Life Sciences Inc Caris Life Sciences is a biotechnology company that offers precision medicine solutions. The company offers ADAPT biotargeting system and Caris molecular intelligence pr...

Drugs and Medications [20 Associated Drugs and Medications listed on BioPortfolio]

Oxygen [A.M. Home Diagnostics Inc. dba Healthline]

Oxygen

Cystografin dilute diatrizoate meglumine injection usp 18% [Bracco Diagnostics Inc.]

CYSTOGRAFIN DILUTE Diatrizoate Meglumine Injection USP 18%

Cystografin diatrizoate meglumine injection usp 30% [Bracco Diagnostics Inc.]

CYSTOGRAFIN Diatrizoate Meglumine Injection USP 30%

Multihance [Bracco Diagnostics Inc]

These highlights do not include all the information needed to use MultiHance safely and effectively. See full prescribing information for MultiHance. MultiHance (gadobenate dimeglumine) injection Init...

Reno-30 diatrizoate meglumine injection usp 30% [Bracco Diagnostics Inc.]

RENO-30 Diatrizoate Meglumine Injection USP 30%

PubMed Articles [264 Associated PubMed Articles listed on BioPortfolio]

Component resolved diagnostics for hymenoptera venom allergy.

Component-resolved diagnostics makes use of defined allergen molecules to analyse IgE-mediated sensitizations at a molecular level. Here, we review recent studies on the use of component-resolved diag...

Exploring the Case for a Global Alliance for Medical Diagnostics Initiative.

In recent years, the private and public sectors have increased investments in medical diagnostics for low- and middle-income countries (LMICs). Despite these investments, numerous barriers prevent the...

Comprehensive genetic study of cystic fibrosis in Slovak patients in 25 years of genetic diagnostics.

Cystic fibrosis (CF) has one of the longest histories in hereditary disease molecular diagnostics. However, identification of causative mutations in the CFTR gene is complicated by over two thousand c...

Advances in point-of-care technologies for molecular diagnostics.

Advances in miniaturization, nanotechnology, and microfluidics, along with developments in cloud-connected point-of-care (POC) diagnostics technologies are pushing the frontiers of POC devices toward ...

Local enamel demineralization diagnostics and treatment.

The article describes focal enamel demineralization - the most common disease of teeth hard tissues. Local and general factors of this pathological process advent and development were described. The m...

Clinical Trials [158 Associated Clinical Trials listed on BioPortfolio]

Caris Molecular Intelligence Registry

This data collection Registry is a multi-center, observational outcomes Database designed to collect data on the demographics, presentation, diagnosis, treatment, resource use, quality of ...

LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer

This is a pilot feasibility study assessing the use of a commercial molecular profiling service in the UK's National Health Service (NHS). The impact of knowledge of a patient's molecular ...

Differential Diagnostics of Etiology of Acute Infections

Method for diagnostics of the origin of infections (bacterial vs viral) based on the identification of activation markers of blood neutrophils and monocytes will be developed.

Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study

With a completely bedside blood culture diagnostics system (BACTEC blood culture system in combination with the Accelerate ID/AST System) it is possible to optimize the initial antimicrobi...

MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

The purpose of this study is to assess the performance of the HTLV Blot 2.4 from patients with the following conditions: infected with HTLV and neurological conditions with symptoms simila...

Companies [890 Associated Companies listed on BioPortfolio]

CDX Holdings

CDX Holdings is the parent company of Caris Diagnostics and Caris Molecular Diagnostics, whose principal subsidiary is Caris MPI. Through its subsidiaries, CDX Holdings is a leading provider of th...

Caris Diagnostics

Caris Diagnostics (Caris Dx) is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. C...

Sekisui Diagnostics

A Sekisui Chemical company since 2011, Sekisui Diagnostics is a leading supplier of high quality products to diagnostic manufacturers, clinical laboratories and physician offices ...

Innotrac Diagnostics Oy

Founded 1995Located in Turku, FinlandInnotrac Diagnostics provides health care professionals with a comprehensive immunoassay platform and test portfolio for rapid and high quality results in cardiac ...

Cleveland Diagnostics, Inc.

Cleveland Diagnostics, Inc., is a clinical-stage biotechnology company developing technology to improve cancer diagnostics. Its Solvent Interaction Analysis (SIA) technology inves...

More Information about "Caris Diagnostics" on BioPortfolio

We have published hundreds of Caris Diagnostics news stories on BioPortfolio along with dozens of Caris Diagnostics Clinical Trials and PubMed Articles about Caris Diagnostics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Caris Diagnostics Companies in our database. You can also find out about relevant Caris Diagnostics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...


Corporate Database Quicklinks



Searches Linking to this Company Record